TY - JOUR
T1 - C4 Nephritic Factors in C3 Glomerulopathy
T2 - A Case Series
AU - Zhang, Yuzhou
AU - Meyer, Nicole C.
AU - Fervenza, Fernando C.
AU - Lau, Winnie
AU - Keenan, Adam
AU - Cara-Fuentes, Gabriel
AU - Shao, Dingwu
AU - Akber, Aalia
AU - Fremeaux-Bacchi, Veronique
AU - Sethi, Sanjeev
AU - Nester, Carla M.
AU - Smith, Richard J.H.
N1 - Funding Information:
We thank the patients whose participation made this study possible. Support: This research was supported in part by National Institute of Diabetes and Digestive and Kidney Diseases R01-110023 to Drs Smith and Nester. The funding agency had no role in study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication. Financial Disclosure: The authors declare that they have no other relevant financial interests. Contributions: Research area and study design: YZ, VF-B, RJHS; data acquisition:YZ, NCM, FCF, WL, AK GC-F, DS, AA, SS; data analysis and interpretation: YZ, CMN, RJHS; supervision or mentorship: RJHS. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. Peer Review: Evaluated by 2 external peer reviewers, the Pathology Editor, an Associate Editor, and Editor-in-Chief Feldman.
Publisher Copyright:
© 2017 The Authors
PY - 2017/12
Y1 - 2017/12
N2 - Background C3 glomerulopathy (C3G) defines a group of rare complement-mediated kidney diseases with a shared underlying pathophysiology: dysregulation of complement in the fluid phase and glomerular microenvironment. Dysregulation can be driven by autoantibodies to C3 and C5 convertases. Study Design Case series. Setting & Participants 168 patients with C3G (dense deposit disease, 68; C3 glumerulonephritis, 100) selected from our C3G biobank. Outcomes Patient-purified immunoglobulin Gs were tested for C4 nephritic factors (C4NeFs). These autoantibodies recognize C4b2a, the C3 convertase of the classical pathway of complement. Measurements C4NeFs were detected using a modified hemolytic assay. Results C4NeFs were identified in 5 patients, 4 of whom had C3 glomerulonephritis. C4NeFs were associated with dysregulation of C3 and C5 convertases, and they appear to stabilize these convertases in a dose-dependent manner. C4NeFs also appear to protect C4b2a from decay mediated by soluble CR1 and C4 binding protein. The stabilizing activity of the autoantibodies was further demonstrated by using heat treatment to inactivate complement. C4NeFs were not detected in 150 patients with another complement-mediated kidney disease, atypical hemolytic uremic syndrome. They were also absent in 300 apparently healthy controls. Limitations In addition to C4NeFs, 2 patients had positive findings for other autoantibodies: one patient also had autoantibodies to factor H; the other patient also had autoantibodies to C3bBb (C3NeFs). Conclusions The finding of C4NeFs in a small percentage of patients with C3G highlights the challenge in identifying autoantibodies that drive complement dysregulation and underscores the complexity of the autoantibody repertoire that can be identified in these patients.
AB - Background C3 glomerulopathy (C3G) defines a group of rare complement-mediated kidney diseases with a shared underlying pathophysiology: dysregulation of complement in the fluid phase and glomerular microenvironment. Dysregulation can be driven by autoantibodies to C3 and C5 convertases. Study Design Case series. Setting & Participants 168 patients with C3G (dense deposit disease, 68; C3 glumerulonephritis, 100) selected from our C3G biobank. Outcomes Patient-purified immunoglobulin Gs were tested for C4 nephritic factors (C4NeFs). These autoantibodies recognize C4b2a, the C3 convertase of the classical pathway of complement. Measurements C4NeFs were detected using a modified hemolytic assay. Results C4NeFs were identified in 5 patients, 4 of whom had C3 glomerulonephritis. C4NeFs were associated with dysregulation of C3 and C5 convertases, and they appear to stabilize these convertases in a dose-dependent manner. C4NeFs also appear to protect C4b2a from decay mediated by soluble CR1 and C4 binding protein. The stabilizing activity of the autoantibodies was further demonstrated by using heat treatment to inactivate complement. C4NeFs were not detected in 150 patients with another complement-mediated kidney disease, atypical hemolytic uremic syndrome. They were also absent in 300 apparently healthy controls. Limitations In addition to C4NeFs, 2 patients had positive findings for other autoantibodies: one patient also had autoantibodies to factor H; the other patient also had autoantibodies to C3bBb (C3NeFs). Conclusions The finding of C4NeFs in a small percentage of patients with C3G highlights the challenge in identifying autoantibodies that drive complement dysregulation and underscores the complexity of the autoantibody repertoire that can be identified in these patients.
KW - C3 glomerulonephritis
KW - C3 glomerulopathy (C3G)
KW - C3 nephritic factors (C3NeFs)
KW - C4 nephritic factors (C4NeFs)
KW - autoantibodies
KW - case series
KW - complement dysregulation
KW - complement-mediated renal disease
KW - dense deposit disease (DDD)
KW - immune deposits
KW - kidney biopsy
UR - http://www.scopus.com/inward/record.url?scp=85028000096&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028000096&partnerID=8YFLogxK
U2 - 10.1053/j.ajkd.2017.07.004
DO - 10.1053/j.ajkd.2017.07.004
M3 - Article
C2 - 28838767
AN - SCOPUS:85028000096
SN - 0272-6386
VL - 70
SP - 834
EP - 843
JO - American Journal of Kidney Diseases
JF - American Journal of Kidney Diseases
IS - 6
ER -